MicroRNA-616 promotes the progression of ovarian cancer by targeting TIMP2
Related Experiment Video
Updated: Feb 11, 2026

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression
Published on: August 28, 2012
Zhongbo Chen1, Jianqing Zhu1, Yiming Zhu1
1Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China.
Abstract:
MicroRNAs (miRNAs), a group of short (~20 nt) non‑coding RNAs, play critical roles in the development and progression of ovarian cancer (OC). The role of miR‑616, a recently identified cancer-associated miRNA, has never been examined in OC before. The present study demonstrated that the level of miR‑616 was increased in OC tissues. A high miR‑616 level was associated with poor tumor differentiation and advanced tumor-node-metastasis (TNM) stage. Survival analysis revealed that an elevated level of miR‑616 was associated with poor prognosis of OC patients as demonstrated by decreased overall survival (OS) and disease‑free survival (DFS). Overexpression of miR‑616 promoted the migration, invasion as well as epithelial-mesenchymal transition (EMT) of A2780 cells. Knockdown of miR‑616 inhibited these biological functions. Immunohistochemical (IHC) staining revealed that OC tissues with high miR‑616 levels exhibited a significantly decreased level of E‑cadherin and an increased level of N‑cadherin. Furthermore, tissue inhibitor of metalloproteinases 2 (TIMP2) was confirmed to be a direct downstream target of miR‑616. Inhibition of TIMP2 expression was required for the promoting effects of miR‑616 on the metastasis and EMT of OC cells. Collectively, this study revealed that miR‑616 promoted the progression of OC by enhancing cell migration, invasion and EMT.
More Related Videos
10:35An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
11:51Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis
Published on: November 18, 2019
Related Concept Videos
MicroRNAs
MicroRNAs
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Eukaryotic Promoter Region
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...